Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

Saved in:
Bibliographic Details
Published inLeukemia Vol. 28; no. 5; pp. 1158 - 1163
Main Authors Zhong, Y, El-Gamal, D, Dubovsky, J A, Beckwith, K A, Harrington, B K, Williams, K E, Goettl, V M, Jha, S, Mo, X, Jones, J A, Flynn, J M, Maddocks, K J, Andritsos, L A, McCauley, D, Shacham, S, Kauffman, M, Byrd, J C, Lapalombella, R
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.05.2014
Nature Publishing Group
Subjects
631/136/2091
631/250/1619/40
631/80/84
692/699/67/1990/283/1895
B-Lymphocytes - drug effects
B-Lymphocytes - immunology
Bone marrow
Cancer
Cancer Research
Cell activation
Cell growth
Cell migration
Cell Movement - drug effects
Cell proliferation
Cell Proliferation - drug effects
Cellular control mechanisms
Cellular proteins
Chronic lymphocytic leukemia
Critical Care Medicine
Dehydrogenases
Development and progression
Drug resistance
Drug therapy
Enzyme inhibitors
Gene expression
Genetic aspects
Health aspects
Hematology
Humans
Hydrazines - pharmacology
Intensive
Internal Medicine
Kinases
letter-to-the-editor
Letters to the editor
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - immunology
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Lymphatic leukemia
Lymphocyte Activation - drug effects
Lymphocytes B
Medical prognosis
Medicine
Medicine & Public Health
Multiple myeloma
Oncology
Stem cells
Triazoles - pharmacology
United States > US
China
Iowa City Iowa
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2014.9